Aspen Pharmacare (OTCMKTS:APNHY) Shares Gap Up Following Dividend Announcement

Key Points

• Aspen Pharmacare shares rose significantly, gapping up from a previous closing price of $5.24 to an opening price of $5.70, following a dividend announcement.
• The company declared a dividend of $0.0725 per share, representing an impressive dividend yield of 138.0%, which will be paid on October 21st.
• Aspen Pharmacare has a debt-to-equity ratio of 0.37 and maintains a quick ratio of 1.18, highlighting its financial stability.

Aspen Pharmacare (OTCMKTS:APNHY - ) gapped up before the market opened on Wednesday following a dividend announcement from the company. The stock had previously closed at $5.24, but opened at $5.70. Aspen Pharmacare shares last traded at $5.45, with a volume of 520 shares traded. The newly announced dividend which will be paid on Tuesday, October 21st. Stockholders of record on Monday, October 6th will be paid a $0.0725 dividend. This represents a dividend yield of 138.0%. The ex-dividend date of this dividend is Friday, October 3rd.

Aspen Pharmacare Stock Performance

The company has a quick ratio of 1.18, a current ratio of 2.21 and a debt-to-equity ratio of 0.37. The stock has a 50 day moving average price of $6.10 and a 200 day moving average price of $6.85.

Aspen Pharmacare Company Profile

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.